Your browser doesn't support javascript.
loading
LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy.
Mamun, M A A; Zhang, Yu; Zhao, Jin-Yuan; Shen, Dan-Dan; Guo, Ting; Zheng, Yi-Chao; Zhao, Li-Juan; Liu, Hong-Min.
Affiliation
  • Mamun MAA; Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, China, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Henan Province for Drug Quality and Evaluation, Institute of Drug Discovery and Development, School of Pharmaceutical Sciences
  • Zhang Y; Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, China, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Henan Province for Drug Quality and Evaluation, Institute of Drug Discovery and Development, School of Pharmaceutical Sciences
  • Zhao JY; Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, China, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Henan Province for Drug Quality and Evaluation, Institute of Drug Discovery and Development, School of Pharmaceutical Sciences
  • Shen DD; Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
  • Guo T; Key Laboratory of Endometrial Disease Prevention and Treatment Zhengzhou China, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
  • Zheng YC; Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, China, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Henan Province for Drug Quality and Evaluation, Institute of Drug Discovery and Development, School of Pharmaceutical Sciences
  • Zhao LJ; Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, China, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Henan Province for Drug Quality and Evaluation, Institute of Drug Discovery and Development, School of Pharmaceutical Sciences
  • Liu HM; Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, China, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Henan Province for Drug Quality and Evaluation, Institute of Drug Discovery and Development, School of Pharmaceutical Sciences
J Biomed Sci ; 30(1): 60, 2023 Jul 31.
Article in En | MEDLINE | ID: mdl-37525190
ABSTRACT
Dysregulation of various cells in the tumor microenvironment (TME) causes immunosuppressive functions and aggressive tumor growth. In combination with immune checkpoint blockade (ICB), epigenetic modification-targeted drugs are emerging as attractive cancer treatments. Lysine-specific demethylase 1 (LSD1) is a protein that modifies histone and non-histone proteins and is known to influence a wide variety of physiological processes. The dysfunction of LSD1 contributes to poor prognosis, poor patient survival, drug resistance, immunosuppression, etc., making it a potential epigenetic target for cancer therapy. This review examines how LSD1 modulates different cell behavior in TME and emphasizes the potential use of LSD1 inhibitors in combination with ICB therapy for future cancer research studies.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Microenvironment / Neoplasms Limits: Humans Language: En Journal: J Biomed Sci Year: 2023 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Microenvironment / Neoplasms Limits: Humans Language: En Journal: J Biomed Sci Year: 2023 Document type: Article